KRAS Mutation Detection by Compact Sequencing Compared with Real-Time Detection PCR and Pyrosequencing in the Routine Clinical Laboratory

Patients with colorectal cancer and KRAS mutations do not benefit from treatment with monoclonal antibodies to epidermal growth factor receptor (EGFR). Therefore, KRAS mutation detection has been introduced into clinical practice. Several clinical laboratory methods have been established such as direct sequencing, pyrosequencing, and real-time detection PCR, which show varying detection limits and differing grades of automation.